Recently, tyrosine kinase inhibitors targeting anaplastic lymphoma kinase (ALK) have been approved for the treatment of ALK-positive non-small-cell-lung-cancer (NSCLC) 2. This evidence concerns the gene ALK and non-small cell lung carcinoma.